Expression of PTEN tumor suppressor gene has been known to dephosphorylate the phosphatidylinositol 3' kinase (PI3K) products on the 3 prime inositol ring, resulting in reduced Akt activation. Loss of PTEN expression in OPM2 and D47 human myeloma lines led to high Akt activity toward insulin-like growth factor I (IGF-I). In contrast, mouse plasma cell tumor (PCT) lines, expressing wild type PTEN, did not respond to IGF-I for Akt activation. We demonstrated here that endogenous PTEN played a negative role in controlling Akt activity in both mouse PCT and NIH3T3 fibroblast lines by using anti-sense oligonucleotides against PTEN. To determine the role of src-homology 2-containing inositol 5' phosphatase (SHIP) in regulating the PI3K/Akt pathway, we manipulated its expression by down-regulation and overexpression in myeloma, PCT and NIH3T3 lines and analysed Akt activation. Our results showed that SHIP, unlike PTEN, did not affect Akt activity in all systems analysed, despite its ability to dephosphorylate a PI3K product. Although SHIP2 expression resulted in suppression of interleukin-6-mediated mitogen-activated protein kinase activation, expression of SHIP and SHIP2 in a PTEN-null myeloma line did not suppress Akt activity. Biologically, expression of only PTEN, but not SHIP and SHIP2, resulted in growth inhibition and increased apoptosis in OPM2 myeloma line. Together, our results have established the role of PTEN, but not SHIP and SHIP2, in negatively regulating the PI3K/Akt cascade and in myeloma leukemogenesis.
Introduction
Activation of phosphatidylinositol 3' kinase (PI3K) pathway leading to generation of phosphatidylinositol (PI) phosphates, mainly PI3,4P 2 (PIP 2 ) and PI3,4,5P 3 (PIP 3 ), has been linked to many signaling pathways, such as those triggered by platelet-derived growth factor (PDGF), nerve growth factor, insulin-like growth factor I (IGF-I), interleukin 3 and extracellular matrix engagement (Rameh and Cantley, 1999) . Stimulation of PI3K activity stands as the central signaling crossover controlling many biological responses including anti-apoptosis, cytoskeletal reorganization, chemotaxis, and cell proliferation (Fruman et al., 1998) . Both PIP 2 and PIP 3 are able to bind to several proteins, such as Akt serine/threonine kinase and phosphoinositide-dependent kinase 1 (PDK1), through their pleckstrin-homology (PH) domains (Klippel et al., 1997; Stokoe et al., 1997; Toker and Cantley, 1997) . In response to growth factor or cytokine stimulation, the elevated PIP 2 and PIP 3 recruit Akt from the cytosol to the plasma membrane, where it can be phosphorylated by PDK1 and another kinase on Thr 308 and Ser 473, respectively (Alessi et al., 1996) . Phosphorylation of Akt on Thr 308 (Alessi et al., 1997; Casamayor et al., 1999; Pullen et al., 1998) by PDK1 with subsequent Ser 473 phosphorylation is absolutely required for Akt activation (Alessi et al., 1996) .
Active Akt phosphorylates several substrates including BAD (del Peso et al, 1997) , glycogen synthase kinase-3 (Cross et al., 1995) , forkhead transcription factors (Brunet et al., 1999; Cross et al., 1995; Rena et al., 1999; Tang et al., 1999) , and proteins involved in nitric oxide synthesis (Dimmeler et al., 1999; Fulton et al., 1999) , leading to the suppression of apoptosis by different mechanisms. The pivotal role of PI3K in B lymphocyte proliferation has been suggested by the finding that knockout of p85 a subunit of PI3K resulted in the failure of B cell proliferation and development (Fruman et al., 1999; Suzuki et al., 1999) . A truncated version of p85 associated with the p110 catalytic subunit has also been isolated from transformed lymphoid cells (Jimenez et al., 1998) . The oncogenic Akt was originally cloned from a T cell lymphoma where it was truncated and fused to the viral sequence (Bellacosa et al., 1991) . All these data point to the critical importance of PI3K and Akt in hematopoietic, particular lymphoid, cell transformation.
PTEN (phosphatase and tensin homologue deleted on chromosome 10, also called MMAC1 or TEP1) is a recently cloned tumor suppressor gene (Li and Sun, 1997; Steck et al., 1997) , which preferentially dephosphorylates lipid substrates (Maehama and Dixon, 1998; Myers et al., 1998) . Dephosphorylation of PI3K products, PIP 2 and PIP 3 , by PTEN on the 3 prime of the inositol ring leads to decreased levels of these phospholipids and a simultaneous reduction in Akt activity (Cantley and Neel, 1999; Maehama and Dixon, 1998) . Loss of PTEN expression has been detected in many cancers, including glioblastomas, breast and prostate carcinomas, and several syndromes with multiple tumor incidence (Di Cristofano and Pandolfi, 2000; . Knockout of one allele of the PTEN gene in mice led to high tumor incidence in different tissues (Di Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998) . Re-expression of PTEN in those PTEN negative lines resulted in either induction of apoptosis or inhibition of cell cycle progression, depending on the cell types analysed (Cantley and Neel, 1999) .
SHIP (Src homology 2-containing inositol 5' phosphatase) is a recently identified lipid phosphatase, which hydrolyzes the 5 prime phosphate of the inositol ring from inositol 1,3,4,5-tetraphosphate and PIP 3 (Damen et al., 1996; Lioubin et al., 1996) . It is mainly expressed in hematopoietic cells and tyrosine phosphorylated in vivo in response to cytokine and growth factor stimulation (Rohrschneider et al., 2000) . Its phosphatase activity toward PIP 3 has been linked to suppress several signaling pathways, including the Bruton tyrosine kinase and Akt (Aman et al., 1998; Bolland et al., 1998) , leading to the inhibition of hematopoietic cell proliferation and survival (Lioubin et al., 1996; Liu et al., 1997) . The SHIP knockout mice exhibited chronic hyperplasia of myeloid cells resulting in splenomegaly, lymphoadenopathy, and myeloid infiltration of lung, leading to lower survival rate of mice (Helgason et al., 1998) . Furthermore, blocked B cell development, enhanced mature B lymphoid cell proliferation and high serum Ig production were observed in SHIP7/7 mice Liu et al., 1998) . Loss of SHIP expression in vivo led to high Akt activation in bone marrow-derived mast cells in response to cytokine stimulation (Liu et al., 1999) and purified B lymphocytes in response to B cell receptor (BCR) activation or BCR-FcgII receptor (FcgIIR) crossing . The SHIP7/7 B cells exhibited stronger proliferation and reduced apoptosis (Brauweiler et al., 2000; Helgason et al., 2000; Liu et al., 1998) , suggesting that SHIP plays a negative role in B cell signaling.
Multiple myeloma (MM) is a terminal B-cell malignancy, which accounts for 1% of total cancers. To date, no cure has been achieved (Desikan et al., 1999; Kyle, 2001) . Likewise, the etiology and signaling pathways leading to tumorigenesis have not been fully elucidated (Hallek et al., 1998) . Our previous results have demonstrated that high Akt activation was detected in two of four MM lines, which was caused by the loss of PTEN expression . In contrast, no Akt activation was observed in eight mouse PCT lines, which represent a model for human myeloma (Potter, 1997) . Although signaling through the IGF-I receptor/insulin receptor substrate/PI3K cascade was shared in the two species Li et al., 2000) , Akt activation was only detected in two human myeloma cells null of PTEN expression, but not in mouse PCT lines with higher PI3K activity. The role of lacking PTEN in leading to high Akt activation in MM lines was demonstrated by re-expressing PTEN and analysing for the suppression of Akt . However no direct evidence was provided in our previous study showing the role of endogenous PTEN in suppressing Akt activation in mouse PCT lines. This was due to the failure of using the phosphatase inactive mutant (C124S) of PTEN to reverse the original inhibition of Akt activity in a PCT line. Moreover, we were not able to solve the discrepancy for different Akt activities in mouse NIH3T3 fibroblasts versus PCT lines. While both types of cells express PTEN proteins, only NIH3T3 fibroblasts were able to respond to PDGF for Akt activation .
To establish the importance of endogenous PTEN in suppressing Akt activity, we have utilized anti-sense oligonucleotides (ASO) against PTEN in different cell types. Furthermore, we ectopically expressed SHIP in both myeloma and NIH3T3 lines, in order to assess its potential involvement in regulating Akt activation. SHIP2, another member of SHIP family phosphatases (Pesesse et al., 1997 (Pesesse et al., , 1998 , was also expressed in OMP2 line. We were interested to know if SHIP and SHIP2 would act similarly as PTEN to negatively regulate the PI3K/Akt pathway in myeloma leukemogenesis.
Results
Endogenous PTEN in the NIH3T3 line is functional in suppressing Akt activity NIH3T3 line was the first to be used to dissect Akt activation in response to PDGF (Franke et al., 1995) . The extremely high Akt activity toward PDGF in this line (Franke et al., 1995; Hyun et al., 2000) raised one possibility that the endogenous PTEN may be mutated or not functional. Our reversed trascriptase-polymerase chain reaction with subsequent sequencing analysis indicated that PTEN gene is not mutated or internally deleted (data not shown). To determine if endogenous PTEN was functional, we down-regulated PTEN RNA level by treating cells with modified ASO against PTEN. Treatment with PTEN specific ASO45 and ASO47 resulted in a 41 and 36% reduction of PTEN protein levels, respectively, when compared to that treated with control ASO48 (Figure 1a ). When Akt activity was measured using peptide RPRAATF as the substrate, significant increases in Akt activity were detected in both ASO45 and ASO47 treated cells, particularly upon PDGF stimulation (Figure 1b) . Reblotting the membrane used in panel A with antiAkt showed that ASO treatment did not affect Akt expression levels in each condition (Figure 1c ). This result suggests that endogenous PTEN plays a role in inhibiting both basal and PDGF-induced Akt activities in the NIH3T3 fibroblasts, despite that PDGF stimulation resulted in high Akt activation (Franke et al., 1995; Hyun et al., 2000) .
Down-regulation of PTEN in a mouse PCT line also leads to increased Akt activity
To investigate if the endogenous PTEN in PCT lines would also possess a similar inhibitory effect on Akt activation as that in NIH3T3 fibroblasts, we screened four PTEN expressing PCT lines (7.2, 12.2, 121.1 and 128.3) for potential ASO uptake using fluorescencelabeled c-raf oligonucleotide as the indicator. By testing several methods efficient for the transfection of suspension cells, we found that only 121.1 PCT line induced by abl/myc viruses was able to incorporate the ASO using the Fugene 6 transfection. After three rounds of ASO treatment, the PTEN expression levels were reduced by 76 and 80% with ASO45 and ASO47, respectively, when compared with that of control ASO48 treated cells (Figure 2a) . The basal level of Akt activity was induced significantly when compared with that of ASO48 treated cells (Figure 2b ; for ASO45, P=0.0047 and for ASO47 P=0.0129). Induction of basal Akt activity in 121.1 line was similar to that of NIH3T3 line, indicating that the endogenous PTEN functions as a negative regulator of the PI3K/ Akt pathway in both cell systems. As expected, Akt protein levels were not altered upon ASO treatment ( Figure 2c ). We were not able to determine whether IGF-I or serum could induce Akt activity upon downregulating PTEN in this abl/myc PCT line, since the constitutive v-Abl tyrosine kinase activity prohibited most ligands from further stimulating signaling pathways . Nevertheless, our results indicate that endogenous PTEN negatively regulates basal Akt activity in a PCT line.
SHIP is not important in regulating the PI3K/Akt pathway in the NIH3T3 cells
Recent results suggested that SHIP, another phospholipid phosphatase, inhibited Akt activation in mature B cells after BCR and FcgIIR cross-linking (Aman et al., 1998) . We tested if expression of SHIP endogenously would also contribute to the inability of mouse PCT lines to activate Akt. We were also interested to know whether high Akt activation in NIH3T3 fibroblasts would be contributed by its lacking of SHIP expression (Muraille et al., 1999) . Thus, we expressed the SHIPWT, its catalytic inactive mutant (D675A), and NPXY motif mutant (Y917F/Y1020F) in NIH3T3 cells and determined their expression by a Western blot analysis ( Figure 3 , bottom panel). The Y917F/Y1020F mutant has been known to abolish its association with Shc through Shc phosphotyrosine binding domain (Lamkin et al., 1997) . Expression of SHIPWT did not significantly affect the Akt phosphorylation on Ser 473 ( Figure 3 , top panel) or Akt activity on a substrate (data not shown) stimulated by PDGF and IGF-I, when compared to that of D675A mutant expressing line. In contrast, we observed some inhibition of Akt phosphorylation upon expressing the Y917F/Y1020F mutant in this cell line. Since this mutant only affects protein -protein interaction, but not SHIP phosphatase activity, we speculate that some SHIP interacting protein may be critical for Akt activation in NIH3T3 cells.
Down-regulation of endogenous SHIP does not affect Akt activity in a PCT line
SHIP expression was easily detectable in most PCT lines by a direct Western blot analysis ( Figure 4a and data not shown). However, no expression was observed in NIH3T3 and D47 MM lines (Figures 3 and 4a ). We were able to detect SHIP expression in OPM2 myeloma line only by immunoprecipitation (see Figures 4a and 5a ). To test whether low Akt activity in mouse PCT lines would be attributable by endogenous SHIP expression in addition to PTEN, we utilized ASO technique to down-regulate SHIP from the 121.1 abl/myc PCT line (Figure 4a ). Three rounds of ASO treatment resulted in 48 and 94% reduction of SHIP by specific ASO74 and ASO78, respectively, when compared with control ASO848 treatment. In striking contrast to ASO against PTEN (Figure 2 ), significantly reduced SHIP expression did not affect Akt activity at the same line ( Figure 4b ;
Figure 3 SHIP is not critical for suppressing the PI3K/Akt pathway in NIH3T3 fibroblasts. NIH3T3 cells and various SHIP infectants were serum starved overnight and either untreated or stimulated with BB (100 ng/ml) or IGF-I (100 ng/ml) for 10 min. Equivalent amounts of cell lysates were subjected to a direct Western blot analysis using anti-P-Akt (top panel). Intensity of each band was arbitrarily defined by using PDGF and IGF-I treated bands in the D675A line as the bases. The same membrane was reblotted with anti-SHIP (bottom panel) P=0.8330 for ASO74; P=0.7248 for ASO78). The ASO treatment against SHIP did not change Akt protein level (Figure 4c ). This result correlates with negative effect on Akt activity by expressing SHIP in the NIH3T3 line and indicates that expression of SHIP endogenously does not contribute to low Akt activity in a mouse PCT line.
SHIP does not suppress the PI3K/Akt pathway in response to IGF-I in a human myeloma line
Whether low or no SHIP expression in human PTENnull myeloma lines contributed to high Akt activation was tested by the overexpression of SHIP in the OPM2 line. Retroviral gene transfer resulted in expression of PTENWT and C124S mutant in the OPM2 line ( Figure  5a , left panel), as previously reported . Expression of endogenous SHIP was detectable in the sizes of 145, 125 and 110 kDa after anti-SHIP immunoprecipitation followed by the same antibody blot analysis (Figure 5a , right panel). Overexpression of SHIPWT and Y917F/Y1020F mutant was observed in the similar sizes in the respective infectants When these infectants and the parental OPM2 line were stimulated by IGF-I, Akt phosphorylation was almost abolished in the PTENWT line, but not greatly affected in the line expressing the C124S mutant ( Figure 5b , top panel), consistent with our previous report . In contrast to PTENWT, expression of SHIPWT or its 917F/1020F mutant did not affect the Akt phosphorylation. Correlating with the Akt phosphorylation, the slower migrating band disappeared only in the PTENWT infectant, but not in any other infectants and OPM2 parental line toward IGF-I stimulation (Figure 5b, bottom panel) . These results indicate that SHIP is not critical in antagonizing the PI3K/Akt pathway in PTEN-null myeloma cells in response to IGF-I stimulation.
Expression of SHIP2 does not affect Akt activity in response to IGF-I and IL-6 stimulation in OPM2 line SHIP2 is another member of SHIP family, possessing similar phosphatase activity as SHIP toward PIP 3 (Pesesse et al., 1998) . Its expression in PTEN-null glioblastoma resulted in the inhibition of Akt activation (Taylor et al., 2000) . To exclude any possibility that overexpressed SHIP may not function as a phosphatase, we expressed Flag-tagged SHIP2WT and its truncation mutant of the catalytic region (DRV-SHIP2) in the OPM2 line (Figure 6a ). The DRV-SHIP2 is about 13 kD smaller than SHIPWT (155 kD) in size. Like SHIPWT expression, expression of SHIP2WT or its catalytic inactive mutant did not affect IGF-I-induced Akt phosphorylation on Ser 473 (Figure 6b and data not shown for the DRV-SHIP2), contrasting greatly to PTEN re-expression. Reblotting the same membrane with anti-p70S6K showed that IGF-I-induced slow migration of p70S6K, another downstream molecule of PI3K, was not affected in any lines analysed, even in the PTENWT line ( Figure  6b , bottom panel). This result was consistent with our previous conclusion that PTEN was involved only in regulating Akt, but not p70S6K, negatively in terminal B cell tumors from both mouse and human origins .
To rule out the possibility that anti-phospho-Akt antibody on Ser 473 may not fully reflect Akt activity, we performed an Akt activity assay using Histone H2B as the substrate in the PTEN, SHIP and SHIP2 infected cells (Figure 6c ). Interleukin 6 (IL-6), a major myeloma growth and survival factor (Klein et al., 1995) , was shown to induce Akt activation in OPM2 line dependent on PI3K (Zhang et al, submitted) and was also included. As seen in Figure 6c , both basal and IGF-I induced Akt activities were reduced by 42 and 60%, respectively, in the PTENWT cells, when compared with those in OPM2 line. However, no reduction of Akt activity was observed in SHIP and SHIP2 lines toward IGF-I. IL-6 stimulation of OPM2 line resulted in a weak increase in H2B phosphorylation. Similar to IGF-I stimulation, Akt activity induced by IL-6 was reduced only in the PTENWT line, but not in the SHIPWT and SHIP2WT lines (Figure 6c) . Together, our results indicate that expression of SHIP2, like SHIP, does not negatively affect Akt activity in response to IGF-I and IL-6, which contrasts to PTEN in myeloma Akt signaling. Expression of SHIP2 negatively regulates mitogenactivated protein kinase (MAPK) activity in response to IL-6 in OPM2 cells
To demonstrate the functional expression of SHIP and SHIP2 in OPM2 line, we analysed their tyrosine phosphorylation in response to IGF-I and IL-6. As shown in Figure 7a , the 145 kD endogenous SHIP tyrosine phosphorylation was increased in response to IL-6. SHIPWT overexpression resulted in constitutive phosphorylation and this phosphorylation was strongly induced by IL-6 (Figure 7a, left panel) . Interestingly, expression of the 917F/1020F mutant suppressed its own and endogenous SHIP phosphorylation toward IL-6. Expression of SHIP2WT in the size of 155 kD resulted in even stronger constitutive phosphorylation than that of SHIP, and this phosphorylation was induced by IL-6. Tyrosine phosphorylation of DRV-SHIP2 was reduced when compared to SHIP2WT (compare Figures 6a and 7a) . Interestingly, proteins in the sizes of 110 and 100 kD, co-precipitated with SHIPWT and SHIP2WT, respectively, were detected by anti-phosphotyrosine (anti-pTyr) and their association was increased upon IGF-I and IL-6 stimulation (Figure 7a, marked by asterisks) . Another associating protein in the size of 155 kD was detectable in antipTyr blots after IL-6 stimulation in both SHIPWT and SHIP2WT infectants. The identities of these phosphoproteins are currently unknown.
To seek further evidence of functional expression of SHIP and SHIP2 in addition to their phosphorylation, we measured MAPK phosphorylation by anti-phospho-MAPK Western blot analyses. As we recently observed (Zhang et al, submitted), IL-6 stimulation resulted in over twofold increases in MAPK phosphorylation on both p44 and p42 isoforms in both parental and most infected cells (Figure 7b , top panel). In contrast to no effect on Akt, expression of SHIP2WT, but not DRV-SHIP2, suppressed basal and IL-6-induced MAPK phosphorylation by 30 and 36%, respectively, suggesting that phosphatase activity of SHIP2 and/or its tyrosine phosphorylation is required for suppressing MAPK activity. No increase in MAPK phosphorylation was detected in response to IGF-I in OPM2 line, as we recently observed (Zhang et al, manuscript submitted). Interestingly, we did not observe any reduction of MAPK phosphorylation in the PTENWT line. Reblotting the membrane with anti-MAPK antibody showed similar loading in all lanes (Figure 7b, bottom panel) . These results clearly suggest that while SHIP and SHIP2 expression does not affect Akt activation in response to IGF-I and IL-6, SHIP2 expression functionally regulates MAPK activity. On the other hand, re-expression of PTEN specifically targets Akt, but not p70S6K and MAPK pathways in myeloma cells.
PTEN, but not SHIP and SHIP2, suppresses growth and induces strong apoptosis of OPM2 cells
Myeloma is a terminal B-cell malignancy characterized by its resistance to apoptosis. Activation of Akt pathway together with the loss of PTEN has been tightly linked to the suppression of apoptosis in many cell systems and in vivo (Cantley and Neel, 1999) . Thus, we were interested to know whether re-expression of PTEN, SHIP or SHIP2 would affect myeloma apoptosis. Dexamethasone (Dex) has been used clinically to treat myeloma patients (Kyle, 2001 ) and was included here for apoptosis-induction. As shown in Figure 8a , more apoptotic cells were detected in the PTENWT infectant, when compared to any other lines analysed by Annexin V staining in regular culture media. Dex treatment for 72 h resulted in increases in apoptosis of the parental line and this treatment reached to the maximal apoptosis in the PTENWT line. The ethanol used as the solvent to dilute the Dex did not affect the apoptosis, indicating the specific effect of Dex on myeloma apoptosis. Expression of the C124S mutant of PTEN did not enhance cell death, Figure 6 Expression of SHIP2 in OPM2 line does not affect IGF-I and IL-6 induced Akt activity. (a) OPM2 and its SHIP2 infectants were serum starved for 2 h, stimulated with IGF-I (100 ng/ml) or IL-6 (10 ng/ml) for 10 min and lysed. Equivalent amounts of cell lysates were immunoprecipitated with anti-Flag followed by same antibody immunoblot analysis. (b) Akt phosphorylation on Ser 473 was detected using anti-P-Akt antibody (top panel). Same membrane was reblotted with anti-p70S6K (bottom panel). (c) The OPM2 cells and infectants were similarly treated as shown in panel A and subjected to an Akt activity assay using Histone H2B as the substrate. Phosphorylated H2B is shown. Fold increases in Akt activities were detected using a PhosphoImager suggesting that the phosphatase activity of PTEN is critical for inducing apoptosis. Expression of the SHIPWT had no significant effect on apoptosis. Proapoptotic effect upon PTENWT expression was further demonstrated by the increased caspase 3 activity (Figure 8b) . Again, expression of the C124S mutant, SHIPWT, and SHIP2WT did not increase caspase 3 activity, fully supporting the specific role of PTEN, but not SHIP and SHIP2 in myeloma apoptosis.
By using a 3-[4,5-dimethlthiazol-2-yl]-2,5-dyphenyl tetrazolium bromide (MTT) colorimetric proliferation assay, we found that expression of PTENWT, but not C124S, SHIPWT and SHIP2WT, significantly inhibited cell growth (Figure 8c ). Taken together, our results support the role of PTEN in negatively regulating the PI3K/Akt pathway, which may be directly linked to myeloma apoptosis and growth inhibition. In contrast, SHIP and SHIP2 are not important in inhibiting Akt pathway, inducing apoptosis and suppressing myeloma growth.
Discussion
In the present study, we have further investigated the negative role of PTEN in regulating the PI3K/Akt pathway and affecting myeloma biology. By comparing the Akt activation in mouse fibroblasts with the terminal B cell tumors from both human and mouse species, we have established the role of endogenous PTEN in blocking Akt activation in response to IGF-I and PDGF. In contrast, the potential effect of SHIP and SHIP2 on Akt activation was excluded in both fibroblasts and terminal B cell tumors. Finally, we have provided the strong evidence that expression of PTEN, but not SHIP and SHIP2, induced apoptosis and growth inhibition of a myeloma line.
Although studies have shown the suppression of the PI3K/Akt cascade by re-expressing PTEN in the original PTEN-null cancer cells (Furnari et al., 1997; Haas-Kogan et al., 1998; Shan et al., 2000; Weng et al., 1999; Wu et al., 1998) , we were not able to demonstrate the role of endogenous PTEN in suppressing Akt activity in mouse PCT lines previously . This was due to the failure of the catalytically inactive mutant of PTEN (C124S) to act in a dominant negative fashion to reverse the inhibition of endogenous PTEN on Akt. By using the ASO specific for PTEN, we were able to reduce the endogenous protein levels in NIH3T3 cells by 36 to 41% with the resultant increase in Akt activity in response to PDGF-BB stimulation by twofold. Whereas some previous reports using the re-expression technique in PTEN deleted and knock-out cells suggested that PTEN might be involved only in controlling the basal Akt activity (Cantley and Neel, 1999) , our data support its negative role in both basal and growth factor-stimulated Akt activity. Similar down-regulation of PTEN was also achieved in a mouse PCT line with the significant induction of Akt activity, suggesting that endogenous PTEN is also functional in mouse PCT lines. Our results are in accordance with the finding of PTEN knockout cells, where the basal Akt activity was much higher than that of the control mice .
In striking contrast to PTEN, expression of SHIP in both fibroblasts and myeloma cells did not suppress Akt activation. Down-regulation of SHIP did not increase Akt activity in a mouse PCT line, either. These results suggest that endogenous and overexpressed SHIP is not able to affect the PI3K/Akt pathway negatively. Increased tyrosine phosphorylation of endogenous and overexpressed SHIP toward IL-6 was detected, indicating SHIP translocation from the cytosol to the plasma membrane. However, IL-6 induced Akt activation was not reduced in the SHIPWT line. These results clearly suggest that overexpressed SHIP should get access to the PIP 3 , mainly generated in the plasma membrane fraction of cells after growth factor stimulation, but fails to affect Akt negatively.
No negative inhibition of PI3K/Akt pathway was further demonstrated by expressing SHIP2, another SHIP family member, which was also shown to dephosphorylate PIP 3 . Expression of SHIP2WT resulted in very strong tyrosine phosphorylation, particularly in response to IL-6. Furthermore, expression of SHIP2WT, but not its catalytic inactive mutant, caused reduced MAPK phosphorylation toward IL-6. However, SHIP2 expression did not affect Akt activation in response to IL-6 or IGF-I. These results give no doubt that both SHIP members are not able to negatively regulate the PI3K/Akt pathway, at least in myeloma, PCT and fibroblast cells. This is a surprising result to us, as SHIP and SHIP2 were able to dephosphorylate PIP 3 (Damen et al., 1996; Lioubin et al., 1996) . Furthermore, SHIP in mature B lymphocytes was demonstrated to be a negative player for Akt pathway through FcgIIR and BCR crosslinking (Aman et al., 1998) . Knockout of SHIP in mice resulted in prolonged cell survival of both myeloid cells and B lymphocytes, which was believed to act through the increased Akt activation Liu et al., 1999) . A recent study using SHIP2 in a PTENnull glioblastoma line demonstrated the suppressed (b) OPM2 and its infectants were cultivated for 24 h in the presence of 5% FBS and lysed. Caspase 3 activity was measured using a kit according to the manufacturer's instruction. (c) OPM2 and its infectants were cultivated for 48 h in the presence of 5% FBS and a MTT colorimetric assay was performed. Significant inhibition of growth by PTENWT re-expression was marked by an asterisk (P50.01) basal and PDGF induced Akt activities with the concomitant growth arrest in G1 phase of cell cycle (Taylor et al., 2000) .
Several possibilities exist, which may explain the failure of SHIP and SHIP2 to block the PI3K/Akt pathway in our study. First, it is still possible that PIP 2 plays a critical role in inducing Akt activation through its binding to the PH domain of Akt. Dephosphorylation of PIP 3 by SHIP and SHIP2 generates the PIP 2 , thus still leading to Akt activation. The PIP 2 was shown to bind to PH domain of Akt and induced its activation in vitro (Klippel et al., 1997) . On the other hand, dephosphorylation of PIP 3 and PIP 2 on the 3'inositol ring by PTEN should render the products fully inactive for Akt binding and activation. Second, PTEN may possess much stronger phosphatase activity than SHIP and SHIP2 due to its localization or its affinity toward the PI3K products. Finally, we do not know if any pathways are missing in myeloma cells, which prohibit SHIP and SHIP2, but not PTEN from suppressing Akt.
We do not believe that the redundancy of endogenous SHIP versus overexpressed one caused no negative regulation of Akt in OPM2 line. The endogenous SHIP in the 121.1 line was not able to inhibit Akt activity in the down-regulation experiment (Figure 4b ). SHIP expression in NIH3T3 cells, which do not express SHIP endogenously, did not inhibit Akt, either. Expression of SHIP2 in OPM2 line suppressed IL-6 stimulated MAPK activation in the presence of endogenous SHIP. On the other hand, overexpression of SHIP, with increased tyrosine phosphorylation toward IL-6, did not affect MAPK activation. These data demonstrate the distinctive roles played by each phosphatase in signal transduction. Finally, no effect of SHIP and SHIP2 on Akt inactivation and myeloma apoptosis correlates with the biological consequence of SHIP knockout mice, which showed only hyperplasia of myeloid cells, but no tumor formation (Helgason et al., 1998) . No tumor formation and any disturbance of hematopoietic cell signaling in SHIP2+/7 and SHIP27/7 mice, respectively, was reported (Clement et al., 2001) , despite that SHIP2 is also expressed in hematopoietic cells (Muraille et al., 1999) . The OPM2 myeloma line lacks PTEN expression, but does express endogenous SHIP, substantiating the original speculation that SHIP, unlike PTEN, is not a tumor suppressor gene and is not mutated in any cancer (Rohrschneider et al., 2000) . Contrasting the negative results of expressing SHIP and SHIP2 in OPM2 lines on Akt activity, we reproducibly detected the reduced MAPK phosphorylation in SHIP2WT, but not in DRV-SHIP2 line. Our result correlates with SHIP7/7 B cells showing increased MAPK activation in response to BCR aggregation and BCRFcgIIR cross-linking Liu et al., 1998) . Whether SHIP2 suppression of MAPK activation in myeloma cells is dependent upon its phosphatase activity or its tyrosine phosphorylation remains to be determined.
Correlating well with the suppression of the PI3K/ Akt pathway by PTEN, we observed the increased apoptosis and slower growth of myeloma cells reexpressing PTEN. However, these biological consequences were not detected in the same cells expressing the SHIPWT or SHIP2 construct. Interestingly, reexpression of PTENWT, but not its C124S mutant sensitized Dex-induced apoptosis. Dex treatment of myeloma has been reported to induce apoptosis through Pyk2 tyrosine kinase activation , Muc-1 core protein induction , NF-kB inactivation (Feinman et al., 1999) and induction of cell cycle kinase inhibitors (Urashima et al., 1997) . We did not observe any change in PI3K activity in Dex-treated OPM2 line (Zhang et al, submitted) , suggesting that the cooperative effect of PTEN expression with Dex may act by targeting different pathways. Although the mechanism of PTEN sensitization of Dex-induced apoptosis is not fully elucidated, the result is of great significance for designing new strategy of treating myeloma patients. For example, re-expression of PTEN in those patients lacking PTEN expression or with low PTEN expression can be chosen for PTEN gene therapy, which may trigger stronger apoptosis upon chemotherapy.
In summary, our results show that PTEN plays a physiological role in suppressing the PI3K/Akt pathway when it is expressed in a wild type configuration. In contrast, SHIP and SHIP2 have been excluded from regulating the PI3K/Akt cascade in fibroblasts and tumors from terminal B-lymphocyte origins. Finally, our data demonstrate the pivotal role of PTEN, but not SHIP and SHIP2, in affecting myeloma apoptosis and growth, thus linking the PI3K/PTEN/Akt pathway to myeloma leukemogenesis.
Materials and methods

Site-directed mutagenesis, subcloning and retroviral infection
The human wild type PTEN (PTENWT) and C124S catalytically inactive mutant constructs were kindly provided by J Dixon (University of Michigan). Subcloning them in the pLXIN retroviral system (Clontech) and expressing them in myeloma cells have been described . The mouse wild type SHIP (SHIPWT) and Y917F/Y1020F mutant cDNA constructs in the pApuro vector were kindly provided by T Kurosaki (Kansai Medical University, Japan). The inserts were released by EcoRI and SalI and subcloned to a modified pLXIN vector using the EcoRI and XhoI bidirectional cloning. To establish a phosphatase inactive mutant of SHIP (D675A), we designed the mutagenesis primers as follows: Sense primer 5'-cttgccttcctggtgtgctcgagtcctctggaagtc-3' and Antisense primer 5'-gacttccagaggactcgagcacaccaggaaggcaag-3', and subjected them to a mutagenesis reaction according to the manufacturer's instruction (Stratagene; Quick-Mutagenesis system). The mutant clone generates a new XhoI restriction enzyme site (underlined in the sequences) and was confirmed by a sequence analysis.
The pcDNA3 vector containing wild type SHIP2 (SHIP2WT) and a catalytic domain deletion mutant (DRV-SHIP2) fused with Flag tag, kindly provided by S Decker (Pfizer Global Research and Development) (Prasad et al., 2001) was digested with HindIII and EcoRI. The released inserts with the Flag tag were subcloned to pLXIN by bluntend ligation after filling in reaction. The pLXIN vectors containing SHIPWT, D675A, Y917F/Y1020F, SHIP2WT, and DRV-SHIP2 were transfected to PT67 and psi2 packaging lines and supernatants were harvested after neomycin selection. The viral producing supernatants from SHIP, SHIP2 and PTEN constructs were utilized for infecting OPM2 and NIH3T3 lines in the presence of 8 mg/ ml of polybrene (Sigma) for 12 h and selected in the presence of 750 mg/ml of G418 (Invitrogen).
Cell culture
The NIH3T3 fibroblasts were cultivated in the Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum (FBS) and antibiotics. Culture of MM and PCT lines has been described previously Li et al., 2000) .
Cell stimulation, lysis, immunoprecipitation and immunoblot analysis
The NIH3T3 and its infectants were serum-starved overnight and the MM and PCT lines were serum-starved for 2 h. Cells were either untreated or stimulated with IGF-I (Intergen; 100 ng/ml), IL-6 (R&D Systems, 10 ng/ml) or PDGF-BB (Upstate Biotechnology Inc., UBI; 100 ng/ml) for 10 min and lysed in a Triton X-100 containing buffer (Li et al., 1998) . Equivalent amounts of cell lysates (100 mg per sample) were denatured and electrophoresed on 8% SDS -PAGE gels, transferred to Immobilon P (Millipore), and immunoblotted with anti-PTEN (Santa Cruz Biotech, Inc.), anti-Akt (Santa Cruz Biotech, Inc.), anti-P-Akt (Ser473; New England BioLab), anti-P-MAPK (Thr 202/Tyr 204; New England BioLab), or anti-SHIP (BD Pharmigen). For immunoprecipitation, equivalent amounts of cell lysates (1 -2 mg per sample) were immunoprecipitated with anti-SHIP or antiFlag (Kodak) followed by anti-Flag or anti-pTyr (UBI) immunoblot analysis. Proteins were detected using an ECL system from Amersham.
ASO treatment of NIH3T3 cells and Akt activity assay
NIH3T3 cells were plated in 10 cm petri-dishes pre-treated with fibronectin (Calbiochem). When the cells reached 50% confluence, they were treated with 200 nM of ASO, using oligofectamine from Invitrogen as the carrier. Chimeric phosphorothioate ASO directed against PTEN and SHIP were kindly provided by Isis Pharmaceuticals, Inc. and synthesized as described previously (McKay et al., 1999) . The specific antisense oligonucleotides used in this study were as follows: antisense PTEN, 5'-ACATAGCGCCTCT-GACTGGG-3' (Isis 116845; ASO45 in the text); antisense PTEN, 5'-CTGCTAGCCTCTGGATTTGA-3' (Isis 116847; ASO47 in the text); and 6 mismatch control to ASO47, 5'-CTTCTGGCATCCGGTTTAGA-3' (Isis 116848; ASO48 in the text). Cells were treated twice with ASO in 2 consecutive days. Afterwards, cells were serum starved overnight and either untreated or stimulated with PDGF-BB in 1, 10 and 100 ng/ml concentrations for 10 min. Equivalent amounts of cell lysates were subjected to an Akt activity assay using a kit from UBI. Briefly, 1 mg of protein from each treatment was immunoprecipitated with 1 mg of anti-Akt (sheep, UBI). Washed beads were coincubated with Akt substrate (RPRAATF) for 15 min in the presence of reaction buffer and 32p-g-ATP. Twenty-five ml of reaction was subsequently spotted on phosphocellulase paper, washed with 1% phosphoric acid, and counted in a beta counter for a measurement of counts per minute (c.p.m.).
ASO treatment of 121.1 abl/myc PCT line with PTEN and SHIP sequences and Akt activity assays
The 121.1 cells were treated three times in the three consecutive days with 200 nM ASO against PTEN using Fugene 6 reagent as a carrier (Roche). Briefly, 200 nM ASO was mixed with Fugene 6 for 15 min in room temperature and added to cells in the presence of serum for 5 h. The treatment was washed off and cells were left with the regular culture media overnight. The treating cycle was repeated twice. Afterward, cells were lysed and equivalent amounts of cell lysates were used for a similar Akt activity assay as described for NIH3T3 cells. The anti-sense oligos against SHIP were as follows: antisense SHIP, 5'-GTGATGTTGC-CATGGTTCCA-3' (Isis 168274; ASO74 in the text); antisense SHIP, 5'-ATGGACTCGCTGGCACGCAC-3' (Isis 168278; ASO78 in the text); control oligo, 5'-NNNNNNNNNNNNNNNNNNNN-3' (randomly synthesized universal control; Isis 29848; ASO848 in the text). The methods for down-regulating SHIP RNA and an Akt activity assay were similarly performed as for PTEN in the same 121.1 line.
Akt activity assay using Histone H2B as the substrate The method has been described previously in detail . Anti-pan-Akt serum from New England Biolab was used for immunoprecipitation.
Annexin V staining
The OPM2 myeloma line and its infectants were cultivated with RPMI1640 containing 10% FBS (media), media with ethanol (control for Dex treatment) or media with 10 76 M Dex (Sigma) for 72 h. Afterwards, cells were subjected to an Annexin V staining using a kit from Immunotech according to the manufacturer's instruction.
Caspase-3 colorimetric assay
Different OPM2 expressing lines were cultivated in the concentration of 5610 5 /ml with 5% FBS for 24 h duplicately and lysed. Equivalent amounts of cell lysates were subjected to a caspase 3 activity assay using DEVD as the substrate according to the instruction of the company (R&D Systems). Results were derived from reading the reaction at 405 nm wavelength of an ELISA reader.
MTT proliferation assay
5610
4 cells were plated in 200 ml at each well of 96-well plates containing different OPM2 infected cells in the presence of 5% FBS for 48 h. The MTT dye (Sigma, 125 mg) was added in each well for the last 4 h. Supernatants were decanted and 100 ml DMSO was added. The OD value was read using an ELISA reader at 570 nm with 650 nm as a reference.
Scan analysis, phosphoimaging analysis and statistic analysis
Fold increases in intensity of each band on Western blot analyses were scanned and analysed using Scan Analysis Program (Biosoft). Akt phosphorylation on H2B was scanned and analysed using a PhosphorImager 445 apparatus and software (Molecular Dynamics). The t-test was performed using software from http://www.graphpad.com/ calculators/ttest1.cfm.
